Chinese developers may have had a stellar 2017 compared with recent years but bond investors are increasingly concerned their windfall won’t be enough to withstand the tighter funding conditions this year that could lead to cash crunches.
Last year saw a broad based improvement in finances for China’s property sector, helped by fast-rising property prices. Profit margins rose for the first time in at least five years, while leverage fell to the lowest since 2011, and interest cover rose to a six-year high.
Yet for fixed-income fund managers, rising interest rates and a regulatory squeeze on local funding for the highly indebted sector is the number one worry. Some in the market say developers may even be headed for rare defaults.
“2018 will reflect the difficulty with the higher funding costs,” said Ivy Thung, Singapore-based head of credit research at Nikko Asset Management. “The ability to service debt comes into question if Chinese developers are unable to get financing, or are doing so at much higher interest costs.”
Hot Heal Care Stocks To Buy Right Now: Guaranty Bancorp(GBNK)
- [By WWW.GURUFOCUS.COM]
For the details of PATRIOT FINANCIAL PARTNERS GP, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PATRIOT+FINANCIAL+PARTNERS+GP%2C+LP
These are the top 5 holdings of PATRIOT FINANCIAL PARTNERS GP, LPBanc of California Inc (BANC) – 2,850,564 shares, 27.82% of the total portfolio. Guaranty Bancorp (GBNK) – 1,891,767 shares, 23.36% of the total portfolio. Shares reduced by 19.22%Meta Financial Group Inc (CASH) – 347,069 shares, 14.02% of the total portfolio. Sterling Bancorp (STL) – 1,048,980 shares, 11.07% of the total portfolio. Shares reduced by 16.01%MBT Financial Corp (MBTF) – 2,060,302 sha
- [By Logan Wallace]
Guaranty Bancorp (NASDAQ:GBNK) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday.
Hot Heal Care Stocks To Buy Right Now: BGC Partners, Inc.(BGCP)
- [By ]
BGC Partners (BGCP) : “We’re in a market where Goldman Sachs (GS) got slammed. I’m going with them.”
Ecolab (ECL) : “That’s a terrific situation that I want you to buy more of if it comes down.”
- [By ]
Cramer was bearish on BGC Partners (BGCP) , Dr Pepper Snapple (DPS) , Sterling Construction Co. Inc. (STRL) and B&G Foods (BGS) .
Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.
- [By Logan Wallace]
LPL Financial (NASDAQ: LPLA) and BGC Partners (NASDAQ:BGCP) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
Hot Heal Care Stocks To Buy Right Now: comScore Inc.(SCOR)
- [By Paul Ausick]
comScore Inc. (NASDAQ: SCOR) dropped more than 10% on Tuesday to record a new 52-week low of $20.81. The stock closed at $23.22 on Monday. Volume was about 9 times the daily average of around 470,000 shares. The company’s stock will be de-listed from Nasdaq effective February 8 unless the company receives a stay from the exchange.
Hot Heal Care Stocks To Buy Right Now: Vitality Biopharma (VBIO)
- [By Matthew Briar]
Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”
- [By James E. Brumley]
In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.
We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.
As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.
There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.
It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.
Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo
- [By James E. Brumley]
Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.
Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.
The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.
VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.
Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.
LD Micro was founded in 2006 with the sole purpose of being an independent resource in t
Hot Heal Care Stocks To Buy Right Now: Investors Real Estate Trust(IRET)
- [By Monica Gerson]
General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion.
Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million.
Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million.
Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion.
Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million.
Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million.
UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million.
Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million.
OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million.
8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million.
Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million.
Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million.
Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million.
Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter.
Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share.
Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea
Hot Heal Care Stocks To Buy Right Now: EnSync, Inc.(ESNC)
- [By Peter Graham]
A long term performance chart shows Energous Corporation and potential small cap networking or power peer Acacia Communications (NASDAQ: ACIA) having a run up late last year while small cap Ultralife Corp (NASDAQ: ULBI) is heading back up to previous highs and EnSync Inc (NYSEMKT: ESNC) has underperformed: